Amarin Appoints Dr. Steven L. Smith as Chief Medical Officer
Ticker: AMRN · Form: 8-K · Filed: Jul 29, 2024 · CIK: 897448
| Field | Detail |
|---|---|
| Company | Amarin Corp PLC\UK (AMRN) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $700,000, $1.25, $10.00, $100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, pharmaceuticals
Related Tickers: AMRN
TL;DR
Amarin just hired a new CMO, Dr. Steven L. Smith, from Merck. Big pharma experience incoming.
AI Summary
On July 25, 2024, Amarin Corporation plc announced the appointment of Dr. Steven L. Smith as Chief Medical Officer. Dr. Smith previously served as Senior Vice President and Chief Medical Officer at Aptalis Pharma, and prior to that, held significant roles at Merck & Co., Inc. His appointment is effective immediately and is expected to bolster Amarin's clinical development and regulatory strategies.
Why It Matters
The appointment of a new Chief Medical Officer with extensive experience in cardiovascular drug development could signal a renewed focus on Amarin's pipeline and regulatory pathways for its existing and future therapies.
Risk Assessment
Risk Level: medium — The appointment of a new executive is a standard event, but the specific impact on Amarin's drug development and regulatory success introduces a moderate level of uncertainty.
Key Players & Entities
- Amarin Corporation plc (company) — Registrant
- Dr. Steven L. Smith (person) — Newly appointed Chief Medical Officer
- Aptalis Pharma (company) — Previous employer of Dr. Smith
- Merck & Co., Inc. (company) — Previous employer of Dr. Smith
- July 25, 2024 (date) — Date of earliest event reported
FAQ
Who is the new Chief Medical Officer at Amarin Corporation plc?
Dr. Steven L. Smith has been appointed as the new Chief Medical Officer.
When was the earliest event reported in this filing?
The earliest event reported was on July 25, 2024.
What was Dr. Steven L. Smith's previous role before joining Amarin?
Dr. Smith previously served as Senior Vice President and Chief Medical Officer at Aptalis Pharma.
What is Amarin Corporation plc's industry?
Amarin Corporation plc is in the Pharmaceutical Preparations industry.
Where is Amarin Corporation plc incorporated?
Amarin Corporation plc is incorporated in England and Wales.
Filing Stats: 1,160 words · 5 min read · ~4 pages · Grade level 11.5 · Accepted 2024-07-29 17:30:08
Key Financial Figures
- $700,000 — , Mr. Berg's annual base salary will be $700,000 and he will have the potential to earn
- $1.25 — ent of share price hurdles ranging from $1.25 to $10.00 and the earned option shares
- $10.00 — are price hurdles ranging from $1.25 to $10.00 and the earned option shares are subjec
- $100,000 — t, Mr. Berg has also agreed to purchase $100,000 worth of the Company's shares using his
Filing Documents
- amrn-20240725.htm (8-K) — 53KB
- amrn-ex10_1.htm (EX-10.1) — 225KB
- img195770556_0.jpg (GRAPHIC) — 1KB
- img195770556_1.jpg (GRAPHIC) — 6KB
- img195770556_2.jpg (GRAPHIC) — 1KB
- img195770556_3.jpg (GRAPHIC) — 1KB
- 0000950170-24-087391.txt ( ) — 457KB
- amrn-20240725.xsd (EX-101.SCH) — 32KB
- amrn-20240725_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No . Description 10.1 CEO Employment Agreement, dated July 25, 2024, by and between Amarin Corporation plc and Aaron Berg. 10.2 Option Award Agreement (attached to Exhibit 10.1).* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). *Certain confidential portions omitted via redaction from this Exhibit. * * * ACTIVE/122789132.1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 29, 2024 Amarin Corporation plc By: /s/ Jonathan Provoost Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer & Secretary ACTIVE/122789132.1